Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

by Ramses Sadek, Olivier Rixe, David Munn, Christopher M Smith, Yousef Zakharia, Joseph Drabick, Kenneth F Grossmann, Robert R McWilliams, Montaser F Shaheen, Ravindra Kolhe, Rafal Pacholczyk, Lucinda L Tennant, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi
Published 2021-06-01